Program
AHB-171
A development code. Also written as “AHB-171 Injection”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ausper Biopharma | 22 open or running | phase 2since Jun 2, 2026 | Mar 30, 2026 | Dec 30, 2027phase 1 · NCT07511218 |
| AusperBio Therapeutics | 11 open or running | phase 1since May 7, 2026 | May 7, 2026 | Oct 8, 2027phase 1 · NCT07617194 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2026First study: phase 1 study in Hepatitis B, ChronicNew to Ausper BiopharmaAusper Biopharma · NCT07511218 · 110 planned · China
- May 7, 2026AusperBio Therapeutics's first study: phase 1 study in Hepatitis B, ChronicNew to AusperBio TherapeuticsAusperBio Therapeutics · NCT07617194 · 144 planned · Hong Kong, New Zealand
- Jun 2, 2026Phase 2 study in Hepatitis BPhase 2 reachedAusper Biopharma · NCT07630727 · 138 planned · China
Ahead
- Oct 8, 2027Primary completion: phase 1 study in Hepatitis B, ChronicAusperBio Therapeutics · NCT07617194
- Dec 30, 2027Primary completion: phase 1 study in Hepatitis B, ChronicAusper Biopharma · NCT07511218
- Mar 31, 2029Primary completion: phase 2 study in Hepatitis BAusper Biopharma · NCT07630727
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07630727Hepatitis B · China | 2 | Recruiting | Ausper Biopharma | Mar 31, 2029 | 138 |
| NCT07617194Hepatitis B, Chronic · Hong Kong, New Zealand | 1 | Not yet recruiting | AusperBio Therapeutics | Oct 8, 2027 | 144 |
| NCT07511218Hepatitis B, Chronic · China | 1 | Recruiting | Ausper Biopharma | Dec 30, 2027 | 110 |
How it is read
Names in the registry
- “AHB-171 Injection”, 2 entries
- “AHB-171”, 1 entry
Codes read as this program: AHB171.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 2 studies
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.